• Sumanta Sen
• Biswajit Mukherjee
• Gurudutta Pattanaik
• Manoj Pani

The nanoparticles can be developed into smart drug delivery systems to enhance therapeutic efficacy by manipulating the size, surface characteristics, and selective polymer material. In the present study, we developed nanoformulations using PLGA and investigated the release profiles of encapsulated doxorubicin in different concentrations. Methods: Fluorescence microscopy investigated cellular uptake and localization of nanoparticles in cells. MTT assay, Acridine orange/ethidium bromide (AO/EB) staining, DAPI Staining, and DCFDA staining were performed for the in-vitro anti-cancer evaluation of the synthesized nano-formulation against MCF-7 human breast cancer cell line. The results revealed that PLGA nanoparticles of Doxoribicin demonstrated an IC50 value of 0.906 µg/ml for MCF-7 breast cancer cell line and extended-release of the drug. Doxorubicin can be formulated into PLGA nanoparticles for extended delivery and improved efficacy as a chemotherapeutic agent.

Doxorubicin, MTT assay, MCF-7, Cytotoxicity

"RELEASE PROFILE AND CYTOTOXICITY STUDY OF MODIFIED DOXORUBICIN NANOPARTICLES", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 12, page no.h307-h316, December-2023, Available :http://www.jetir.org/papers/JETIR2312735.pdf

"RELEASE PROFILE AND CYTOTOXICITY STUDY OF MODIFIED DOXORUBICIN NANOPARTICLES", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 12, page no. pph307-h316, December-2023, Available at : http://www.jetir.org/papers/JETIR2312735.pdf